An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, investigators ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly ...

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

To be able to make evidence-based decisions about which test to choose, randomised trials of the comparative benefits of screening tests on colorectal cancer incidence and mortality are needed.

A study found that among US adults eligible for lung cancer screening (LCS), the uptake of colorectal cancer (CRC) and breast cancer screening was nearly fourfold higher than LCS. Among those who ...

Most of us would probably think of smoking or air pollution when it comes to lung cancer risk, but researchers have discovered an intriguing link between the disease and the quality of our diets. The ...

as well as the results of a domestic study titled “Taiwan Lung Cancer Screening In Never-smoker Trial.” With the expanded criteria, people who meet one of two high-risk criteria are eligible for a ...

The Sarasota Memorial Research Institute is participating in a Phase 3 trial of an experimental drug for late-stage ovarian cancer. The drug, Olvi-Vec, is an immunotherapeutic that targets and ...

“We are optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer,” said Robert Bitterman, ...

The National Cancer Institute estimates that more than 600,000 Americans die from cancer every year. In the state of Oklahoma, lung cancer is the most common type. Today, new robotic surgery ...

Beigene Ltd. said it is shutting down development of its anti-TIGIT antibody, ociperlimab (BGB-A1217), after the humanized IgG1-variant monoclonal antibody failed a phase III trial in lung cancer. The ...